Xylem Inc. · XYL · FY2026 Q2 · Calendar Q3 2026

Xylem raises EPS outlook as data-center water demand accelerates

Xylem's Q2 supports a constructive but qualified growth thesis: stronger Applied Water and data-center demand, expanding margins, digital offerings, and targeted acquisitions can offset weakness in electric metering and China. The evidence supports improving mix and earnings momentum more clearly than broad-based revenue acceleration.

Reported Before market openNYSEIndustrials $25.37B market cap
100quality score

Earnings scorecard

Reported versus consensus
Reported EPS $1.46 Consensus $1.35
EPS surprise +8.1% Reported versus consensus
Reported revenue $2.34B Consensus $2.34B
Revenue surprise -0.2% Reported versus consensus

Market reaction

prior-close to event-session close
Stock move +4.0% Event window
SPY move +0.2% Same window
Abnormal move +3.8% Stock minus SPY
Volume 2.2× Versus trailing sessions
Subsequent drift -9.7% Up to 20 sessions
XYLSPY benchmark

Ask FN2 about XYL FY2026 Q2

Transcript, numbers and history already loaded

Free account. Your question opens in FN2 with this report's transcript and numbers attached.

Transcript intelligence

What changed

The quarter added evidence of a sharper mix shift toward Applied Water, data-center solutions, digital platforms, and advanced sensing. Data-center orders rose 300%, EBITDA margin expanded, EPS guidance increased, and management highlighted TriOS, WaterFleet, and a $1 billion annual M&A budget.

Guidance delta

Full-year EPS guidance was raised to $5.55-$5.70; the outlook still calls for modest revenue growth and continued margin expansion.

Key takeaways

  • Q2 showed modest revenue growth, record EPS of $1.46, and EBITDA margin expansion to 23.3%.
  • Applied Water and data-center activity strengthened, with data-center orders up 300% in Q2.
  • Management is reallocating toward industrial growth, digital platforms, and advanced sensing and mobile-treatment capabilities.
  • Electric metering and China remain the main near-term offsets to the stronger Applied Water trajectory.

Management priorities

  • Scale the Vue platform and data-lake offerings.
  • Integrate TriOS and complete the WaterFleet acquisition.
  • Advance portfolio simplification and targeted acquisitions within the $1 billion M&A budget.
  • Focus on AI-related infrastructure, life sciences, mining, and other high-growth industrial verticals.

Follow XYL with an agent that reads every filing, transcript, and price print. Free to start.

Try FN2 free

Earnings History

Estimate Beat Miss Match
XYL EPS earnings history estimate and actual scatter chart 9 reported fiscal quarters and 3 future estimate-only quarters. Q1 '24 estimate $0.84 Q1 '24 actual $0.90, beat Q2 '24 estimate $1.05 Q2 '24 actual $1.09, beat Q3 '24 estimate $1.11 Q3 '24 actual $1.11, match Q2 '25 estimate $1.15 Q2 '25 actual $1.26, beat Q3 '25 estimate $1.23 Q3 '25 actual $1.37, beat Q4 '25 estimate $1.41 Q4 '25 actual $1.42, match Q1 '26 estimate $1.08 Q1 '26 actual $1.12, beat Q2 '26 estimate $1.35 Q2 '26 actual $1.46, beat Q3 '26 estimate $1.45 Q4 '26 estimate $1.63 Q1 '27 estimate $1.21
Show 1 more >

Analyst Consensus ?

ConsensusHold39 ratings
Bullish1948.7%
Neutral1948.7%
Bearish12.6%

Analyst 52W Price Targets

$108.64Current
$107Low
$148.85Average
$170High

Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Sep 24, 2026. Not an FN2 forecast.

Firm-level rating actions

FMP grade actions identify the grading firm, not a named analyst.

FirmRatingPrior ratingActionDate
Jefferies Buy BuyMaintainAug 24, 2026
UBS Neutral NeutralMaintainAug 13, 2026
Stifel Buy BuyMaintainJul 29, 2026
RBC Capital Outperform OutperformMaintainJul 29, 2026
Mizuho Neutral NeutralMaintainJul 29, 2026
Barclays Overweight OverweightMaintainJul 29, 2026
Baird Outperform OutperformMaintainJul 29, 2026
Oppenheimer Outperform OutperformMaintainApr 29, 2026
Citigroup Buy BuyMaintainApr 29, 2026
JP Morgan Overweight OverweightMaintainApr 16, 2026
TD Cowen Hold HoldMaintainDec 5, 2025
Wolfe Research Peer Perform OutperformDowngradeDec 12, 2024
Argus Research Buy BuyMaintainMay 29, 2024
Deutsche Bank Buy HoldUpgradeNov 21, 2023
Melius Research Buy HoldUpgradeOct 2, 2023
Cowen & Co. Outperform OutperformMaintainFeb 14, 2023
Morgan Stanley Overweight OverweightMaintainJan 18, 2023
Raymond James Underperform Market PerformDowngradeJan 4, 2023
Atlantic Equities Overweight NeutralUpgradeNov 16, 2022
Goldman Sachs Neutral NeutralMaintainNov 3, 2022
Credit Suisse Neutral NeutralMaintainNov 2, 2022
Rosenblatt Hold BuyDowngradeOct 1, 2021
Janney Montgomery Scott Neutral NeutralMaintainJun 3, 2020
Janney Capital Neutral NeutralMaintainJun 3, 2020
Canaccord Genuity Hold HoldMaintainFeb 7, 2020
Seaport Global Neutral BuyDowngradeNov 4, 2019
Stifel Nicolaus Buy BuyMaintainMay 3, 2019
BMO Capital Outperform OutperformMaintainOct 31, 2018
Vertical Research Hold SellUpgradeOct 18, 2018
Boenning & Scattergood Neutral OutperformDowngradeNov 28, 2016
Wedbush Neutral OutperformDowngradeApr 11, 2016
Sterne Agee CRT Buy NeutralUpgradeApr 5, 2016
Sterne Agee Buy NeutralUpgradeApr 5, 2016
DA Davidson Neutral NeutralMaintainOct 29, 2014
Keybanc Hold BuyDowngradeOct 30, 2013
Brean Capital Buy HoldUpgradeOct 29, 2013
BB&T Capital Hold BuyDowngradeJul 30, 2013
CL King Neutral BuyDowngradeApr 15, 2013
Ladenburg Thalmann Neutral BuyDowngradeOct 18, 2012
Show less

Named analyst price targets

Upside is calculated against the persisted current price $108.64. FMP does not supply a rating on these named-analyst rows.

FirmAnalyst52W targetPrice when postedUpsideDate
JefferiesAnalyst unavailable$150$113.87 +38.1%Aug 24, 2026
UBSAnalyst unavailable$138$121.93 +27.0%Aug 13, 2026
UBSJoshua Spector$135$116.48 +24.3%Jul 30, 2026
Mizuho SecuritiesAnalyst unavailable$130$124.97 +19.7%Jul 29, 2026
Stifel NicolausAnalyst unavailable$160$124.97 +47.3%Jul 29, 2026
Robert W. BairdMichael Halloran$165$124.97 +51.9%Jul 29, 2026
BarclaysAnalyst unavailable$159$124.97 +46.4%Jul 29, 2026
Stifel NicolausAnalyst unavailable$157$122.78 +44.5%Jul 20, 2026
RBC CapitalAnalyst unavailable$159$124.53 +46.4%Jul 16, 2026
JefferiesStephen Volkmann$140$112.04 +28.9%Jun 25, 2026
UBSAnalyst unavailable$133$116.4 +22.4%Apr 29, 2026
OppenheimerBryan Blair$158$116.4 +45.4%Apr 29, 2026
Stifel NicolausAnalyst unavailable$159$117.91 +46.4%Apr 29, 2026
BarclaysAnalyst unavailable$154$117.91 +41.8%Apr 29, 2026
UBSAnalyst unavailable$132$120.46 +21.5%Apr 21, 2026
Stifel NicolausNathan Jones$163$128.85 +50.0%Apr 14, 2026
UBSJoshua Spector$152$129.4 +39.9%Apr 9, 2026
UBSJoshua Spector$155$128.2 +42.7%Feb 13, 2026
OppenheimerAnalyst unavailable$165$127.02 +51.9%Feb 12, 2026
Goldman SachsAnalyst unavailable$158$126.77 +45.4%Feb 11, 2026
Mizuho SecuritiesAnalyst unavailable$138$128.18 +27.0%Feb 11, 2026
Stifel NicolausAnalyst unavailable$175$128.92 +61.1%Feb 11, 2026
Robert W. BairdAnalyst unavailable$161$128.92 +48.2%Feb 11, 2026
BarclaysWilliam Grippin$166$141.33 +52.8%Jan 7, 2026
Mizuho SecuritiesBrett Linzey$150$137.11 +38.1%Jan 5, 2026
Stifel NicolausAnalyst unavailable$178$153.42 +63.8%Oct 29, 2025
Argus ResearchAnalyst unavailable$170$153.4 +56.5%Oct 29, 2025
Mizuho SecuritiesBrett Linzey$160$150.5 +47.3%Oct 29, 2025
RBC CapitalAnalyst unavailable$176$153.48 +62.0%Oct 29, 2025
Robert W. BairdMichael Halloran$178$153.48 +63.8%Oct 29, 2025
BarclaysWilliam Grippin$172$150.5 +58.3%Oct 29, 2025
BarclaysAnalyst unavailable$165$142.18 +51.9%Sep 18, 2025
UBSAnalyst unavailable$168$143.61 +54.6%Aug 5, 2025
UBSDamian Karas$165$127.5 +51.9%Aug 13, 2024
Robert W. BairdMichael Halloran$170$133.48 +56.5%Jul 31, 2024
OppenheimerBryan Blair$152$139.4 +39.9%May 31, 2024
Argus ResearchJohn Eade$165$140.36 +51.9%May 29, 2024
Mizuho SecuritiesBrett Linzey$135$135.99 +24.3%May 3, 2024
RBC CapitalDeane Dray$162$135.99 +49.1%May 3, 2024
Robert W. BairdMichael Halloran$155$135.99 +42.7%May 3, 2024
Wolfe ResearchBrad Hewitt$143$128.27 +31.6%Apr 8, 2024
RBC CapitalDeane Dray$153$127.25 +40.8%Apr 4, 2024
Stifel NicolausNathan Jones$133$99.8 +22.4%Aug 18, 2023
CitigroupAnalyst unavailable$121$106.85 +11.4%Feb 8, 2023
CitigroupAnalyst unavailable$123$111.23 +13.2%Dec 9, 2022
Atlantic EquitiesRichard Radbourne$129$112.13 +18.7%Nov 16, 2022
Loop Capital MarketsScott Graham$120$127.19 +10.5%Nov 22, 2021
Argus ResearchJohn Eade$150$129.82 +38.1%Nov 12, 2021
CitigroupAndrew Kaplowitz$131$125.7 +20.6%Aug 4, 2021
Goldman SachsBrian K. Lee$107$116.2 -1.5%May 5, 2021
Show less

Track every rating change on XYL the moment it posts. Free to start.

Start free

Company context

Snapshot as of publication

Xylem Inc., together with its subsidiaries, engages in the design, manufacture, and servicing of engineered products and solutions for utility, industrial, and residential and commercial building services settings worldwide. It operates through Water Infrastructure; Applied Water; Measurement and Control Solutions; and Water Solutions and Services segments. The company offers water, wastewater, and storm water pumps and controls and systems; filtration, disinfection, and biological treatment equipment under the Flygt, Ionpure, Leopold, Neptune Benson, Sanitare, Wallace & Tiernan, and Wedeco brands; and pumps, valves, heat exchangers, controls, and dispensing equipment used for water and focuses on the residential, commercial and industrial markets under the Rule, Bell & Gossett, Flojet, Goulds Water Technology, Jabsco, and Lowara brands.…

Historical context

All XYL earnings

Industrials peers this season

Latest reports in the same sector

Latest beats and misses

Who reports next

Get the XYL recap when the next report posts

One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.

Sources

  1. Earnings call transcript and parsed analysis · 2026-07-28T14:06:06.570346+00:00
  2. FN2 earnings calendar · 2026-09-02T01:23:14.593608+00:00
  3. Polygon adjusted daily market bars · 2026-09-24T03:30:53.688260+00:00
  4. Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-09-24T03:30:53.684904+00:00

Methodology

Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.

Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.

Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.

By FN2 Research · Updated · As of 2026-09-24. For educational purposes only; not investment advice.